Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

CDNA vs IMDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDNA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

CDNA Overall Winner 6-Pillar Tally: CDNA 5 – 1 IMDX Matrix Metrics: CDNA 7 – 3 IMDX

As of Nov 19, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CDNA carries a Unified Composite Score of 32.0/100 (SELL) at $71.92 (46.0x Forward P/E, 1.6% operating margin), whereas IMDX carries 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin).

  • Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CDNA 32.0/100 SELL), CDNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -1883.2% operating margin) and revenue trajectory (+39.3% vs. +115.0% YoY).
  • Technical & Structure Timing Caution: CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.4); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDNA vs IMDX
CDNA NASDAQ Head-to-Head Winner
CareDx, Inc.
Services-Medical Laboratories
$71.92
-3.39% 1D
Market Cap $3.9B
TTM Revenue $497M
Forward P/E 46.0x
Beta / 30D Vol 1.22β · 97% Vol
Unified Composite Score
32.0 / 100 SELL
Tech 31.0 Fund 48.0 Flow 70.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.4 · SMA20: $77.68 · SMA50: $68.21
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.91β · 76% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $2.51 · SMA50: $3.10

6-Pillar Scorecard Institutional Category Breakdown (CDNA 5 – 1 IMDX)

Columns: Metric · CDNA · IMDX
1. Valuation Multiples CDNA
Forward P/E 46.0x N/M
Trailing P/E 31.5x N/M
PEG Ratio N/M N/M
EV / Revenue 7.4x 18.8x
2. Growth & Scale IMDX
Revenue Growth (YoY) +39.3% +115.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $497M $2.0M
Market Cap $3.9B $52.1M
3. Profitability & Quality CDNA
Gross Margin 71.0% 55.6%
Operating Margin 1.6% -1883.2%
Net Profit Margin 25.9% 0.0%
Return on Equity (ROE) 33.0% -23603.1%
4. Balance Sheet & Cash Flow CDNA
Cash Generation (TTM) $60M -$31M
Cash Flow Margin 12.0% N/A
Net Cash / Leverage $221M Net Cash $15M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDNA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 64.6% (20th %ile) 99.4% (12th %ile)
Put/Call OI Skew 0.27x (Call-Skewed) 0.08x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CDNA
OpEx & R&D Intensity 69.4% of Rev ($345M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDNA (7) vs IMDX (3)
Institutional Metric CDNA IMDX Criterion Row Edge
Market Capitalization
Scale
$3.9B $52.1M Larger Scale CDNA
Trailing P/E Ratio
Valuation
31.5x N/M Lower Multiple CDNA
Forward P/E Ratio
Valuation
46.0x N/M Lower Multiple CDNA
Revenue Growth (YoY)
Growth
+39.3% +115.0% Higher Growth IMDX
Operating Margin (TTM)
Profitability
1.6% -1883.2% Higher Margin CDNA
Net Profit Margin
Profitability
25.9% 0.0% Higher Margin CDNA
Return on Equity (ROE)
Capital Efficiency
33.0% -23603.1% Higher ROE CDNA
52-Week Range Position
Momentum
75% ($15–$91) 3% ($2–$8) Stronger Trend CDNA
Beta / 30D Volatility
Risk Regime
1.22β · 97% Vol 2.91β · 76% Vol Lower Realized Risk IMDX
Unified Institutional Score
Composite Signal
32.0 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite IMDX
Trailing 12M Revenue (USD)
Operating Scale
$497M $2.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.0% 55.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · 18.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$60M ($221M Net Cash) -$31M ($15M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDNA +46.7 pp
CDNA: +1.67% · IMDX: -45.03%
3M Horizon CDNA +109.7 pp
CDNA: +47.95% · IMDX: -61.75%
6M Horizon CDNA +305.2 pp
CDNA: +233.43% · IMDX: -71.77%
1Y Horizon CDNA +430.13 pp
CDNA: +356.35% · IMDX: -73.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CDNA Revenue IMDX Revenue CDNA Op. Margin IMDX Op. Margin Margin Leader
FY2018 $80M N/A -20.3% N/A CDNA
FY2019 $130M N/A -19.3% N/A CDNA
FY2020 $190M $0M -11.7% -2443.3% CDNA
FY2021 $300M $0M -10.0% -2444.3% CDNA
FY2022 $320M $0M -24.0% -1878.6% CDNA
FY2023 $280M $0M -72.5% -1672.4% CDNA
FY2024 $330M $0M 12.2% -3245.1% CDNA
FY2025 $380M $0M -8.1% -1260.8% CDNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDNA CONSOLIDATION
33d in phase · OBV NEUTRAL
Current IV 64.6%
IV Percentile 20th %ile
Put/Call OI Skew 0.27x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMDX BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 99.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDNA Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $3.9B market capitalization and 1.6% operating margin.
OpEx & R&D Reinvestment 69.4% of Rev ($345M)
90D Engineering Disclosures 0 Published
IMDX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $52.1M market capitalization and -1883.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDNA vs IMDX Key Questions & Quantitative Answers

As of Nov 19, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CDNA carries a Unified Composite Score of 32.0/100 (SELL) at $71.92 (46.0x Forward P/E, 1.6% operating margin), whereas IMDX carries 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CDNA 32.0/100 SELL), CDNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -1883.2% operating margin) and revenue trajectory (+39.3% vs. +115.0% YoY). Technical & Structure Timing Caution: CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.4); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMDX leads the Growth & Scale pillar: CDNA posts +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin), compared with IMDX at +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CDNA cumulative revenue shifted +375.0% while IMDX shifted N/A. In operating R&D and SG&A reinvestment, CDNA deploys 69.4% of Rev ($345M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMDX.

CDNA screens cheaper on headline valuation multiples. CDNA trades at 46.0x Forward P/E, 31.5x Trailing P/E, N/M PEG, and 7.4x EV/Revenue (12.0% FCF margin), whereas IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDNA (33.0% ROE) versus IMDX (-23603.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CDNA carries 64.6% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.27x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.22β · 97% Vol realized risk). By comparison, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.